vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright

Key Points

• HC Wainwright lowered vTv Therapeutics’ price target to $42 from $45 while maintaining a “Buy” rating, implying 21.56% upside from the stock’s $34.55 price.
• Analyst sentiment remains broadly positive, with six Buy, one Hold, and one Sell rating; the consensus rating is “Moderate Buy” with an average price target of $55.83.
• vTv Therapeutics reported a quarterly loss of $1.05 per share, missing the $0.97 consensus estimate, while institutional investors own 17.51% of the company.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) had its target price lowered by equities researchers at HC Wainwright from $45.00 to $42.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's target price indicates a potential upside of 21.56% from the stock's current price.

Several other analysts have also weighed in on the stock. Wall Street Zen raised shares of vTv Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, May 16th. Zacks Research lowered vTv Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, June 11th. BTIG Research lifted their price target on vTv Therapeutics from $49.00 to $57.00 and gave the company a "buy" rating in a report on Thursday, July 16th. Weiss Ratings upgraded shares of vTv Therapeutics from a "sell (d-)" rating to a "sell (d+)" rating in a research report on Monday, May 18th. Finally, Rodman & Renshaw started coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They set a "buy" rating and a $67.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $55.83.

vTv Therapeutics Trading Up 0.5%

VTVT stock traded up $0.16 during trading on Thursday, hitting $34.55. The company had a trading volume of 80,552 shares, compared to its average volume of 54,651. The company has a fifty day moving average price of $33.34 and a two-hundred day moving average price of $34.80. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The company has a market cap of $136.09 million, a P/E ratio of -36.81 and a beta of 0.28.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). On average, analysts expect that vTv Therapeutics will post -2.19 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics in the fourth quarter valued at approximately $221,000. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $731,000. Finally, Geode Capital Management LLC boosted its position in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after purchasing an additional 12,896 shares during the last quarter. Institutional investors own 17.51% of the company's stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source